Perrigo (NYSE:PRGO) Releases FY 2026 Earnings Guidance

Perrigo (NYSE:PRGO) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 2.250-2.550 for the period, compared to the consensus estimate of 2.110. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.1 billion.

Perrigo Stock Performance

PRGO traded up $0.71 during mid-day trading on Wednesday, reaching $12.35. 2,620,663 shares of the company traded hands, compared to its average volume of 3,034,910. The stock has a market capitalization of $1.70 billion, a P/E ratio of -1.20, a P/E/G ratio of 1.34 and a beta of 0.52. The company has a quick ratio of 1.63, a current ratio of 2.76 and a debt-to-equity ratio of 1.23. The company’s fifty day moving average price is $11.10 and its 200-day moving average price is $13.72. Perrigo has a 52-week low of $9.23 and a 52-week high of $28.43.

Perrigo (NYSE:PRGO) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.31 by $0.12. The firm had revenue of $841.80 million during the quarter, compared to analyst estimates of $1.04 billion. Perrigo had a positive return on equity of 9.41% and a negative net margin of 33.51%.Perrigo’s revenue was down 7.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.60 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, sell-side analysts expect that Perrigo will post 2.12 EPS for the current year.

Perrigo Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th will be paid a $0.29 dividend. This represents a $1.16 annualized dividend and a dividend yield of 9.4%. The ex-dividend date is Friday, May 29th. Perrigo’s dividend payout ratio is -11.28%.

Analyst Ratings Changes

PRGO has been the subject of several analyst reports. Jefferies Financial Group restated a “hold” rating on shares of Perrigo in a research note on Thursday, February 26th. Canaccord Genuity Group reduced their price objective on Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, February 27th. Weiss Ratings lowered Perrigo from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 29th. Argus upgraded Perrigo to a “hold” rating in a research note on Wednesday, January 14th. Finally, Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Perrigo presently has an average rating of “Hold” and an average target price of $19.33.

Institutional Trading of Perrigo

Several institutional investors have recently added to or reduced their stakes in PRGO. Fuller & Thaler Asset Management Inc. lifted its stake in Perrigo by 291.9% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 7,824,759 shares of the company’s stock worth $108,921,000 after purchasing an additional 5,828,076 shares during the last quarter. Invesco Ltd. lifted its stake in Perrigo by 134.2% in the fourth quarter. Invesco Ltd. now owns 4,542,415 shares of the company’s stock worth $63,230,000 after purchasing an additional 2,602,724 shares during the last quarter. ION Fund Management Ltd bought a new stake in Perrigo in the fourth quarter worth about $24,499,000. Ion Asset Management Ltd. lifted its stake in Perrigo by 34.7% in the second quarter. Ion Asset Management Ltd. now owns 3,817,621 shares of the company’s stock worth $102,007,000 after purchasing an additional 983,727 shares during the last quarter. Finally, Bridgeway Capital Management LLC bought a new stake in Perrigo in the fourth quarter worth about $9,165,000. Institutional investors own 95.91% of the company’s stock.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.